Association Between Adiponectin Levels with Markers of Atherosclerosis In Patients with Rheumatoid Arthritis

Main Article Content

Tanggo Meriza
Harry Isbagio
Rahmad Mulyadi
Murdani Abdullah


Background: Several studies have shown that atherosclerosis underlying processes of Cardiovascular disease (CVD), increased in rheumatoid arthritis (RA) and occurred early (premature). The cause of accelerated atherosclerosis in RA are still unknown.Adipokines have known that the adipokines play a role in the pathophysiology of RA and CVD. Accumulation of visceral fat associated with dysregulation of adipokinesthat influence the development of the atherosclerotic and disruption plaque. Obesity and pathological changes in fat mass and fat dysfunction as well as a change inthe pattern of secretion of proinflammatory adipokines, may have a correlation between heart disease and rheumatic diseases. Adiponectin is one of the mostwidely-studied adipokines. In RA, adiponectin is involved in the pathophysiology of RA that produces of various proinflammatory and prodestructive molecules. So far, adiponectin has been known to provide antiatherosclerotic effects in patients with non-RA. But, several recent studies in RA patients get opposite results in which increased levels of adiponectin are associated with increased prevalence of atherosclerosis. The effect of adiponectin on atherosclerosis in patient with RA is still unknown.Objective: to determine the relationship of adiponectin with atherosclerosis in patients with rheumatoid arthritis. Methods: This is a cross-sectional study conducted on outpatients of the  rheumatology clinic at Cipto Mangunkusumo General Hospital from January untilApril, 2013. Subjects consisted of 50 patients were diagnosed based on ACR 1987/EULAR 2010 criteria. The collection of data obtained by consecutive sampling and evaluated the patients’ medical data that included age, long-suffering of RA, body mass index (BMI), lipid profile, rheumatoid factor levels, levels of anti-cyclic citrullinated peptide (anti-CCP), C-reactive protein (CRP), erythrocyte sedimentation rates (ESR), blood pressure, fasting blood glucose, 2 hour post prandial blood glucose, ECG, examination of serum adiponectin levels and bilateral carotid ultrasound to measure the carotid artery intima media thickness.Results: From the results of the 50 patients studied, obtained 28 (56%) of patients had increased levels of adiponectin. Atherosclerosis was found in 13 (26%) subjects. The median value was 9.46 μg / ml with the lowest levels of 4 μg/ml and the highestlevels of 24μg/ml. The Spearman’s test showed no significant correlation between adiponectin serum and atherosclerosis in patients with RA (p = 0706 and r = 0.055). The analysis results of the correlation of adiponectin with atherosclerosis based on age, disease duration, ESR, rheumatoid factor, DAS 28, CRP, BMI, dyslipidemia showed no significant correlation.Conclusion : From this study, researchers found no statistically significant correlation between adiponectin levels with marker of atherosclerosis (CIMT) in patients with rheumatoid arthritisKeywords : Adiponectin, Atherosclerosis

Article Details

How to Cite
Meriza, T., Isbagio, H., Mulyadi, R., & Abdullah, M. (2018). Association Between Adiponectin Levels with Markers of Atherosclerosis In Patients with Rheumatoid Arthritis. Indonesian Journal of Rheumatology, 5(1).
Original Article


1. Ozbalkan Z, Efe C, Cesur M, Ertek S, Nasiroglu N, Berneis K et all. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis 2010;212:377-82
2. S. M. Naz and D. P. Symmons, Mortality in established rheumatoid arthritis, Best Practice & Research Clinical Rheumatology. 2007;21:871-83.
3. del-Rincón I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid artritis cohort not explained by traditional cardiac risk factors. Artritis Rheum.2001;44(12):2737-45.
4. Gonzalez A, Maradit-Kremers H, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008;67:64–9.
5. John H, Kitas G, Toms T, Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009;23:71–82.
6. N. Erb, A. V. Pace, K. M. J. Douglas, M. J. Banks, and G. D. Kitas, Risk assessment for coronary heart disease in rheumatoid arthritis andosteoarthritis, Scandinavian Journal of Rheumatology. 2004;33:293-9.
7. Scotece M, Conde J, Gomez R, et al. Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Disease. Mediators of Inflammation 2012; Article ID 125458, 1-14.
8. Gimeno RE, Klaman LD. Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmac 2005;5:122-8
9. Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O. What’s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 2011;7:528–36.
10. T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tobe, Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome, Journal of Clinical Investigation. 2006;116:1784-92.
11. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006,6:772-83.
12. Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, Gonzalez-Juanatey, De Matias JM, Martin J et all. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factor in severe rheumatoid arthritis. Clin Ex Rheum 2008;26:596-603.
13. Scotece M, Conde J, Lopez V, Lago F, Pino J, Gomez-Reino JJ et al. Adiponectin and leptin : New Targets in inflammation. Basic Clin Pharm Toxic. 2013:p1 – 6.
14. Shargorodsky M, Boaz M, Goldberg Y, Matas Z, Gavish D, Fux A et all. Adiponectin and vascular properties in obeses patients: is it a novel biomarker of early atherosclerosis ? Int Journ Obes 2009;33:553-8.
15. Krysiak R, Handzlik-Orlik G, Okopien B. The role of adipokines in connective tissue diseases. Eur J Nutr 2012;51:513-28.
16. Frommer KW, Schäffler A, Büchler C, Steinmeyer J, Rickert M, Rehat Steffen et al. Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis ? Ann Rheum Dis 20012;71:1724-32
17. Ehling A, Scäffler A, Herfarth H et al. The potential of adiponectin in driving arthritis J Immunol 2006;176:4468-78
18. Frommer KW, Zimmermann B, Meier FMP, Schroder D, Heil M, Schäffler A et all. Adiponectin-Meddiated Changes in Effector Cells Involved in the Pathophysiology of Rheumatoid Arthritis. Arthritis Rheum 2010:62;2886-99.
19. Rho YH, Solus J, Sokka T,Oeser A, Chung CP, Gebretsadik T et all. Adipocytokines Are Associated With Radiographiic Joint Damage in Rheumatoid Arthritis. Arthritis Rheum. 2009;60:1906-13.
20. Giles JT, van der Heijde DM, Bathon JM. Association of circulating adiponectin levels with progression of radiographic joint destruction inrheumatoid arthritis. Ann Rheum Dis 2011;70:1562-8.
21. Klein-Wieringa IR, van der Linden MPM, Knevel R,Kwekkeboom JC, van Beelen E, Huizinga TWJ et all. Baseline Serum Adipokine Levels Predict Radiographic Progression in Early Rheumatoid Arthritis. Arthritis Rheum2011:63;2567-74.
22. Dessein PH, Norton GR, Badenhorst M, Woodiwiss AJ, and Solomon A. Rheumatoid Arthritis Impacts on the Independent Relationships between Circulating Adiponectin Concentrations and Cardiovascular Metabolic Risk. Mediators of Inflammation 2013, Article ID 461849, 9 pages.
23. Giles JT, Allison M, Bingham CO,3rd, et al. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis Arthritis Rheum 2009;61:1248-56
24. Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, Sokka T et al. Inflammatory Mediators and Premature Coronary Atherosclerosis in Rheumatoid Arthritis. Arthritis Rheum.2009;61:1580-5.
25. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay M. Carotid IntimaMedia Thickness Predicts the Development of Cardiovascular Events in Patients with Rheumatoid Arthritis. Semin Arthritis Rheum 2009;38:366-71.
26. van-Gaalen F, Visser H, Huizinga TWJ. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibodi tests for rheumatoid artritis. Ann Rheum Dis. 2005;64:1510–12.
27. Gonzalez Gay MA, Gonzalez Juanatey C, Rodriguez-Rodriguez L, MirandaFilloy J.A, Martin J, Llorca J. Lack of association abetween adipokines and ghrelin and carotid intima-media thickness in patients with severe rheumatoid arthritis. Clinical and Experimental Rheumatology 2011;29:358-9.
28. Rho YH, Chung CP, Solus JF, Raggi P, Oeser A, Gebretsadik T et all. Adipocytokines, Insulin Resistance, and Coronary Atherosclerosis in Rheumatoid Arthritis. Arthritis Rheum 2010;62:1259 – 64.
29. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, et al. HLADRB1 and ersistant chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007;15(57):125–32.
30. Van Halm VP, Peters MJ, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009;68:1395–400.
31. Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005;52:2293–9.
32. Fantuzzi G, Adiponectin and inflammation : Consessus and controversy. JAllergy Clin Immunol 2008;121:326-30
33. Behre CJ. Adiponectin: a defense protein in catabolism. J Allergy Clin Immunol 2008;122:1236